Alteration of Laboratory Findings After Radiofrequency Ablation of Hepatocellular Carcinoma: Relationship to Severity of the Underlying Liver Disease and the Ablation Volume

Overview

Journal Clin Mol Hepatol

Specialty Gastroenterology

Date 2015 Apr 3

PMID 25834804

Citations 1

Authors

Sang-Wook Shin

Woo Kyoung Jeong

Sanghyeok Lim

Yongsoo Kim

Jinoo Kim

Affiliations

Soon will be listed here.

Abstract

Background/aims: To investigate sequential changes in laboratory markers after radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC) and the relationship of these changes to the severity of the underlying liver disease.

Methods: This retrospective analysis included 65 patients (44 males, 21 females) who underwent RFA of HCC. Hematologic and biochemical markers were assessed at the pre-RFA period and 1 day, 2-3 days, and 1-2 weeks after RFA. We classified the subjects into two groups: Child-Pugh A (n=41) and Child-Pugh B (n=24). The ablative margin volume (AMV) of each patient was measured. We analyzed the changes in laboratory profiles from the baseline, and investigated whether these laboratory changes were correlated with the AMV and the Child-Pugh classification.

Results: Most of the laboratory values peaked at 2-3 days after RFA. AMV was significantly correlated with changes in WBC count, hemoglobin level, and serum total bilirubin level (Pearson's correlation coefficient, 0.324-0.453; P<0.05). The alanine aminotransferase (ALT) level varied significantly over time (P=0.023).

Conclusions: Most of the measured laboratory markers changed from baseline, peaking at 2-3 days. The ALT level was the only parameter for which there was a significant difference after RFA between Child-Pugh A and B patients: it increased significantly more in the Child-Pugh A patients.

Citing Articles

Combination Therapy With Lenvatinib and Radiofrequency Ablation for Patients With Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh Class A Liver function: A Pilot Study.

Wang F, Numata K, Komiyama S, Miwa H, Sugimori K, Ogushi K Front Oncol. 2022; 12:843680.

PMID: 35600400 PMC: 9114706. DOI: 10.3389/fonc.2022.843680.

References

Curley S, Izzo F, Ellis L, Nicolas Vauthey J, Vallone P . Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg. 2000; 232(3):381-91. PMC: 1421151. DOI: 10.1097/00000658-200009000-00010. View

Wood T, Rose D, Chung M, Allegra D, Foshag L, Bilchik A . Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications. Ann Surg Oncol. 2000; 7(8):593-600. DOI: 10.1007/BF02725339. View

Livraghi T, Goldberg S, Lazzaroni S, Meloni F, Ierace T, Solbiati L . Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology. 2000; 214(3):761-8. DOI: 10.1148/radiology.214.3.r00mr02761. View

Koike Y, Yoshida H, Shiina S, Teratani T, Obi S, Sato S . Changes in hepatic functional reserve after percutaneous tumor ablation for hepatocellular carcinoma: long-term follow up for 227 consecutive patients with a single lesion. Hepatol Int. 2009; 1(2):295-301. PMC: 2716822. DOI: 10.1007/s12072-007-9001-x. View

Nicoli N, Casaril A, Marchiori L, Mangiante G, Marini G, Colombari R . Intraoperative and percutaneous radiofrequency thermal ablation in the treatment of hepatocellular carcinoma. Chir Ital. 2000; 52(1):29-40. View

Lee H, Park S, Kim S, Kweon Y, Tak W, Cho C . Thrombocytopenia represents a risk for deterioration of liver function after radiofrequency ablation in patients with hepatocellular carcinoma. Clin Mol Hepatol. 2012; 18(3):302-8. PMC: 3467434. DOI: 10.3350/cmh.2012.18.3.302. View

Wolf P . Biochemical diagnosis of liver disease. Indian J Clin Biochem. 2012; 14(1):59-90. PMC: 3453559. DOI: 10.1007/BF02869152. View

Buscarini L, Buscarini E, Di Stasi M, Vallisa D, Quaretti P, Rocca A . Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-term results. Eur Radiol. 2001; 11(6):914-21. DOI: 10.1007/s003300000659. View

Goldberg S, Hahn P, Halpern E, Fogle R, Gazelle G . Radio-frequency tissue ablation: effect of pharmacologic modulation of blood flow on coagulation diameter. Radiology. 1998; 209(3):761-7. DOI: 10.1148/radiology.209.3.9844671. View

10.

Cizginer S, Tatli S, Hurwitz S, Tuncali K, vanSonnenberg E, Silverman S . Biochemical and hematologic changes after percutaneous radiofrequency ablation of liver tumors: experience in 83 procedures. J Vasc Interv Radiol. 2011; 22(4):471-8. DOI: 10.1016/j.jvir.2010.12.033. View

11.

Goldberg S, Hahn P, Tanabe K, Mueller P, Schima W, Athanasoulis C . Percutaneous radiofrequency tissue ablation: does perfusion-mediated tissue cooling limit coagulation necrosis?. J Vasc Interv Radiol. 1998; 9(1 Pt 1):101-11. DOI: 10.1016/s1051-0443(98)70491-9. View

12.

Kuroda H, Kasai K, Kakisaka K, Yasumi Y, Kataoka K, Ushio A . Changes in liver function parameters after percutaneous radiofrequency ablation therapy in patients with hepatocellular carcinoma. Hepatol Res. 2010; 40(5):550-4. DOI: 10.1111/j.1872-034X.2009.00613.x. View

13.

Liu Z, Ahmed M, Weinstein Y, Yi M, Mahajan R, Goldberg S . Characterization of the RF ablation-induced 'oven effect': the importance of background tissue thermal conductivity on tissue heating. Int J Hyperthermia. 2006; 22(4):327-42. DOI: 10.1080/02656730600609122. View

14.

Hsin I, Hsu C, Huang H, Huang Y, Lin H, Lee R . Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction. J Clin Gastroenterol. 2011; 45(6):556-62. DOI: 10.1097/MCG.0b013e318210ff17. View

15.

Seror O, Nkontchou G, Ibraheem M, Ajavon Y, Barrucand C, Ganne N . Large (>or=5.0-cm) HCCs: multipolar RF ablation with three internally cooled bipolar electrodes--initial experience in 26 patients. Radiology. 2008; 248(1):288-96. DOI: 10.1148/radiol.2481071101. View

16.

Curley S, Izzo F, Delrio P, Ellis L, Granchi J, Vallone P . Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann Surg. 1999; 230(1):1-8. PMC: 1420837. DOI: 10.1097/00000658-199907000-00001. View

17.

Jarnagin W, Gonen M, Fong Y, DeMatteo R, Ben-Porat L, Little S . Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg. 2002; 236(4):397-406; discussion 406-7. PMC: 1422593. DOI: 10.1097/01.SLA.0000029003.66466.B3. View

18.

Dufour D, Lott J, Nolte F, Gretch D, Koff R, Seeff L . Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem. 2000; 46(12):2050-68. PMC: 7110382. View

19.

Lencioni R, Crocetti L, Cioni D, Della Pina C, Bartolozzi C . Percutaneous radiofrequency ablation of hepatic colorectal metastases: technique, indications, results, and new promises. Invest Radiol. 2004; 39(11):689-97. DOI: 10.1097/00004424-200411000-00007. View

20.

Fan S, Lo C, Liu C, Lam C, Yuen W, Yeung C . Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg. 1999; 229(3):322-30. PMC: 1191696. DOI: 10.1097/00000658-199903000-00004. View